Comparative Pharmacology
Head-to-head clinical analysis: DORYX MPC versus DOXYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORYX MPC versus DOXYCHEL.
DORYX MPC vs DOXYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic